Projects per year
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
SGNDV-005: CTU: A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
Park, J., Chapman, N., TAIDI, G. & Martin, L.
1/05/24 → 17/01/29
Project: Research
-
CIBI363A101: CTU: A Phase 1, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas
Park, J., Chester, C., Chapman, N., TAIDI, G. & Martin, L.
12/04/24 → 28/02/29
Project: Research
-
D3L-001-100: CTU: A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects with HER2-Positive Advanced Solid Tumors.
Park, J., Chester, C., Chapman, N., TAIDI, G. & Martin, L.
4/04/24 → 19/03/29
Project: Research
-
CTU: Phase I/II Study to Assess the Safety, tolerability, Pharmacokinetics and efficacy of JSKN033 in Patients with Advanced or Metastatic Solid Malignant Tumors
Park, J., TAIDI, G., Martin, L. & Chapman, N.
20/03/24 → 15/02/29
Project: Research
-
CIBI133A101: CTU: A Multicentre, Open-label, Phase 1/2 Study of IBI133 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumours
Park, J., TAIDI, G., Chester, C., Chapman, N. & Martin, L.
10/03/24 → 28/02/29
Project: Research
-
Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy
Smith-Uffen, M., Park, J., Parsonson, A., Kiely, B. E. & Vasista, A., 4 Nov 2024, In: Oncologist. 29, 11, p. 922-930 9 p., oyae089.Research output: Contribution to journal › Review article › peer-review
Open AccessFile6 Downloads (Pure) -
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
McLean, L. S., Lim, A. M., Bressel, M., Lee, J., Ladwa, R., Guminski, A. D., Hughes, B., Bowyer, S., Briscoe, K., Harris, S., Kukard, C., Zielinski, R., Alamgeer, M., Carlino, M., Mo, J., Park, J. J., Khattak, M. A., Day, F. & Rischin, D., 5 Feb 2024, In: Medical Journal of Australia. 220, 2, p. 80-90 11 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Citations (Scopus)60 Downloads (Pure) -
PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma
Park, J. J., Hamad, S. A., Stewart, A., Carlino, M. S., Lim, S. Y. & Rizos, H., 28 Feb 2024, In: Oncogenesis. 13, 1, p. 1-9 9 p., 9.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Citations (Scopus)67 Downloads (Pure) -
Safety and efficacy of JSKN003 in patients with advanced/metastatic solid tumors: a first-in-human, dose-escalation, multicenter, open-label, phase I study
Park, J. J., Gao, B., Beecroft, C., Wilkinson, K. J., Parsonson, A., Zhang, K., Yan, X. & Wang, N., 1 Jun 2024, In: Journal of Clinical Oncology. 42, 16 Supplement, 1 p., 3038.Research output: Contribution to journal › Meeting abstract › peer-review
-
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
Day, D., Park, J. J., Coward, J., Markman, B., Lemech, C., Kuo, J. C., Prawira, A., Brown, M. P., Bishnoi, S., Kotasek, D., Strother, R. M., Cosman, R., Su, R., Ma, Y., Yue, Z., Hu, H. H., Wu, R., Li, P. & Tse, A. N., 9 Nov 2023, In: British Journal of Cancer. 129, 10, p. 1608-1618 11 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile3 Citations (Scopus)78 Downloads (Pure)